{"name":"Neil Singla","slug":"neil-singla","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxOazBzV1BPYm9acUVtQmp5YmcxbkVYdVFTMFd5ZzdTSTB4Y2pVcG1XeW9HNHE1dTJwd3RfYWdrdHpubXhBSE5GY3NXanF4XzdlczJZcTk0bi1kREpsbl9CcE92djRRSnZJLXZuNGdXUXB2OW95UF9SNDRGYVBadWQxdnFjaEFoTG1qSExVQ3ZuTWJGSm04Unpfc3JvelFlcFRmVFE?oc=5","date":"2024-08-23","type":"pipeline","source":"statnews.com","summary":"Up and down the ladder: The latest comings and goings - statnews.com","headline":"Up and down the ladder: The latest comings and goings","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxQeFRQdGY2aFY0QXlrX3UzbDlwOEUtNVRBaDlSa0NYZ2FsOEtJdEZNbWMwXzdlRG96emdBMUJCY1pCckdwVDlxWVVNNHhLRXhjMHdTUm1pLVBBQnlLUEFoN1lzcVN3NnM0NHVnXy1pbXZWNlpwcG5RSnNyNmY3OXpuSVhyMmM4YldCMzluZ3YwaC1OQQ?oc=5","date":"2024-08-20","type":"pipeline","source":"Fierce Biotech","summary":"Pain medicine biotech Latigo taps CRO founder for CMO role - Fierce Biotech","headline":"Pain medicine biotech Latigo taps CRO founder for CMO role","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAJBVV95cUxQYXhsSldHemRRblVjdW1kdlBkczBPSGhOTlVqTVpEYVZsU2tQMmNIelNhRksxeUFQLXFoWU5IMHZlWkNVeXJHZ0NGWk5UQ2trRGxjWDNvUTRFUHcyZ3lBVG9WZ1lGMWF3UTNsOVZka21nQzlsRWVkUlNnVjlPU1lFOTUwQXFpNWJkWV9vZFBZZ2o3OTNvSFFLaE5kQlpTTmVwS19ZWEw5ZVNwZ0F0Ti1EOGhXeDg4WGhPcG84S0lCUmljekNReFZOWHIxMFVDa3ZRUkV2TlB5Y0JiRnF6NmNHcXNCdjNvT0dpMmlpcHJPRFdNbHFNSEFwOWZrcU5QelNpUUc3eTVuTGptSGU3dF9IZGRSVlFiRnRCaWp3Z0dfbk5yTXhmRHU1Smwzd3E?oc=5","date":"2024-08-19","type":"trial","source":"PR Newswire","summary":"Latigo Biotherapeutics Announces Positive Phase 1 Data for Lead Non-Opioid Pain Medicine Candidate and Appoints Neil Singla, M.D., Chief Medical Officer - PR Newswire","headline":"Latigo Biotherapeutics Announces Positive Phase 1 Data for Lead Non-Opioid Pain Medicine Candidate and Appoints Neil Sin","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi2gFBVV95cUxOWVVYd3hxQkpmYkNIVnQxUjdFa0RBV3JxaTlUYnVxUUhTd0w3WG5pQW1nZE1MQzZhSl9WdWhsVVJZYV9taG9qcEktZDBLd0xLdEpDU2IzSkNtUm1qUWowRjU5a2NWeDdiM09hekdtVzVfb3B6dE5NUjRBNXpvbzN5OHkzZk9WUmpMNXh5TjhFYmdaeFhqSDl1TjZyckkxR3I1cmxFajdRaGNaTVMwUjFCYkNTOVA4bGtiTFJCV2hIbEhzUS01OURhSWFZanhBUUVjQ0tlelVKSzR0QQ?oc=5","date":"2023-10-12","type":"regulatory","source":"PR Newswire","summary":"South Rampart Pharma Receives U.S. FDA Fast Track Designation for SRP-001 for Acute Pain - PR Newswire","headline":"South Rampart Pharma Receives U.S. FDA Fast Track Designation for SRP-001 for Acute Pain","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2wJBVV95cUxPWVVKcVRiYmt6TGlWMDNIUGlETk9mRllTNk1vVmRLTDNfa19IMXFmRVJVdXNGd293QnA2NTlvTnVoSUJnT3JqLVpfeTJqVk8xZUczSnJOT1UxNmxSdmNXaERGZnpLc2hrTkxZZUZIYTMyZVJjNUtiSVVQTzdXeEhEbnF4bGRoS2RObGtHSElJNmVPSXNXbkU0SVl0MDJ3WFRXdnVqWDFIOGhnb0RXSTZwbWNpRW9ldjlMNkdFMXA3dy04a2hBUlY4bHR6WXR2eFY1MUFBYnlJUUotVWJoWXRZZGFGSl9ZOXFlUnZ6ZjlrdjREU3hwYk56MlpLUW8wR2EtaVdYYUFhTjVKcWk1dm0tdzVoNjUzSEZxMHlGeXo4TnRjV2JZeUZvejYxMUgwa2g3ZXpqZEVRZDFsUU8ySW9mZDJpOWplel9tNUNHMW1LVzVBdW43eTRwYmhmaw?oc=5","date":"2022-12-13","type":"trial","source":"PR Newswire","summary":"Tris Pharma Reports Positive Topline Data from Clinical Study of Investigational Pain Therapy Cebranopadol Showing Significantly Less Potential for Abuse Versus Tramadol and Oxycodone - PR Newswire","headline":"Tris Pharma Reports Positive Topline Data from Clinical Study of Investigational Pain Therapy Cebranopadol Showing Signi","sentiment":"positive"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}